BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced that it has expanded its immunohistochemistry (IHC) test offerings to ...

Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test PALO ALTO, Calif.--(BUSINESS WIRE)-- ...

"As a leader in cancer diagnostics, Ventana is committed to providing unique immunohistochemistry assays for aiding in the diagnosis and management of a variety of cancers," says Ventana President ...

On May 21, Guardant Health, Inc. (NASDAQ:GH) announced adding a full suite of immunohistochemistry to its portfolio of tumor molecular profiling tests. This addition will help oncologists identify the ...

BOSTON--(BUSINESS WIRE)--Boston Cell Standards, a company standardizing tumor tissue testing with the first immunohistochemistry laboratory reference standards, announced the publication of a journal ...

DENVER – Sixteen institutions across Europe collaborated together to show for the first time that a semi-quantitative anaplastic lymphoma kinase (ALK) protein expression test, immunohistochemistry ...

Background: Biomarker testing is essential for guiding first-line treatment decisions in metastatic non–small cell lung cancer (mNSCLC). Despite guideline recommendations, real-world testing patterns ...

Collaboration to produce a machine learning (ML)-based tool that automatically analyzes images of HER2 immunohistochemistry (IHC)-stained tissue slides and reports metrics that can be used to monitor ...

Pediatric Precision Medicine at the National Cancer Center Japan: Prospective Genomic Study of Pediatric Patients with Cancer as Part of the TOP-GEAR Project HER2 status was evaluated using ...

Clinical questions 3, 4, and 5 address less common result groups observed when performing dual-probe ISH testing as described below. 9,10 Since 2013, several laboratory and clinical investigators ...